Corporate ActionJun 29, 2026, 10:31 PM
Nuvectis Pharma Prices $100M Public Offering at $20.00/Share
AI Summary
Nuvectis Pharma, Inc. announced the pricing of its underwritten public offering of 5,000,000 shares of common stock at $20.00 per share, expecting gross proceeds of $100 million. The company has also granted underwriters an option to purchase up to 750,000 additional shares. The net proceeds are intended to fund the development programs of NXP100, NXP200, and NXP900, as well as for hiring, capital expenditures, and general corporate purposes. The offering is anticipated to close around July 1, 2026.
Key Highlights
- Nuvectis Pharma priced an underwritten public offering of 5,000,000 shares of common stock.
- The offering price is set at $20.00 per share.
- Expected gross proceeds to Nuvectis are $100 million.
- Underwriters have a 30-day option to purchase up to 750,000 additional shares.
- Net proceeds will advance development programs for NXP100, NXP200, and NXP900.
- Funds will also be used for hiring, capital expenditures, and general corporate purposes.
- The offering is expected to close on or about July 1, 2026.
Price Impact
More from NVCT